Sun J, Shen D, Gao Y, et al. Onco Targets Ther. 2020;13:7973–7984.
The authors have advised due to an error at the time of figure assembly, on page 7980 is incorrect. The correct is shown below.
Figure 3 Down-regulation of USP8 promotes the degradation of HER-3. (A) Different concentrations of USP8 inhibitor in MGC-803 and si-USP8 cells were used as the control group. (B) Different concentrations of USP8 inhibitor and si-USP8 in NCI-N87, MKN-45 and AGS cells. (C) mRNA level of HER-3 in NCI-N87, AGS and MKN-45 cell lines with USP8 inhibitor and si-USP8 treatment. Expression of HER-3 in NCI-N87 cells with the treatment of USP8 inhibitor (D) and si-USP8 (E) and cycloheximide (CHX, 20 μg/mL) in combination or alone. Expression of HER-3 in MKN-45 cells with the treatment of USP8 inhibitor (F) and si-USP8 (G) and CHX (20 μg/mL) in combination or alone. *P<0.05, **P<0.01.
The authors apologize for this error and advise it does not affect the results of the paper.